CA2473232C - Histamine-3 receptor ligands for diabetic conditions - Google Patents

Histamine-3 receptor ligands for diabetic conditions Download PDF

Info

Publication number
CA2473232C
CA2473232C CA2473232A CA2473232A CA2473232C CA 2473232 C CA2473232 C CA 2473232C CA 2473232 A CA2473232 A CA 2473232A CA 2473232 A CA2473232 A CA 2473232A CA 2473232 C CA2473232 C CA 2473232C
Authority
CA
Canada
Prior art keywords
group
alkyl
term
refers
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2473232A
Other languages
English (en)
French (fr)
Other versions
CA2473232A1 (en
Inventor
Arthur A. Hancock
Eugene N. Bush
Marlon D. Cowart
Peer B. Jacobson
Terry J. Opgenorth
Youssef L. Bennani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/043,848 external-priority patent/US20030134835A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2473232A1 publication Critical patent/CA2473232A1/en
Application granted granted Critical
Publication of CA2473232C publication Critical patent/CA2473232C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA2473232A 2002-01-11 2003-01-10 Histamine-3 receptor ligands for diabetic conditions Expired - Fee Related CA2473232C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/043,848 2002-01-11
US10/043,848 US20030134835A1 (en) 2002-01-11 2002-01-11 Histamine-3 receptor ligands for diabetes conditions
US10/326,546 US20030153548A1 (en) 2002-01-11 2002-12-23 Histamine-3 receptor ligands for diabetic conditions
US10/326,546 2002-12-23
PCT/US2003/000733 WO2003059342A1 (en) 2002-01-11 2003-01-10 Histamine-3 receptor ligands for diabetic conditions

Publications (2)

Publication Number Publication Date
CA2473232A1 CA2473232A1 (en) 2003-07-24
CA2473232C true CA2473232C (en) 2011-03-15

Family

ID=26720877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2473232A Expired - Fee Related CA2473232C (en) 2002-01-11 2003-01-10 Histamine-3 receptor ligands for diabetic conditions

Country Status (8)

Country Link
US (1) US20050113435A1 (https=)
EP (1) EP1474132A1 (https=)
JP (1) JP2006500315A (https=)
AU (1) AU2003235687A1 (https=)
CA (1) CA2473232C (https=)
MX (1) MXPA04006777A (https=)
PL (1) PL373586A1 (https=)
WO (1) WO2003059342A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US6822101B2 (en) 2002-09-16 2004-11-23 Abbott Laboratories Process for preparing amine-substituted benzofurans
WO2004024707A2 (en) * 2002-09-16 2004-03-25 Abbott Laboratories Process for preparing amine type substituted benzofurans
JP2007528860A (ja) * 2003-07-28 2007-10-18 財団法人大阪産業振興機構 血糖降下用組成物
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP1717234A1 (en) * 2005-04-29 2006-11-02 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
CN101674827A (zh) * 2007-03-02 2010-03-17 先灵公司 苯并咪唑衍生物及其使用方法
AR065494A1 (es) * 2007-03-02 2009-06-10 Schering Corp Derivados de piperidina y metodos de uso de los mismos
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096331A (en) * 1976-12-28 1978-06-20 A. H. Robins Company, Incorporated 1-Substituted-3-aminoethoxypyrrolidines
GB2056441B (en) * 1979-07-26 1983-07-06 Kyowa Hakko Kogyo Kk Derivatives of benzo(b)furan and pharmaceutical compositions containing them
US4452986A (en) * 1982-06-08 1984-06-05 The Upjohn Company Imidazolyl-substituted benzofurans
US4447620A (en) * 1982-06-08 1984-05-08 The Upjohn Company Imidazolyl-substituted benzothiophenes
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
WO1998052946A1 (en) * 1997-12-02 1998-11-26 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
EP1268483A1 (en) * 2000-03-17 2003-01-02 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
NZ534582A (en) * 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors

Also Published As

Publication number Publication date
PL373586A1 (en) 2005-09-05
EP1474132A1 (en) 2004-11-10
JP2006500315A (ja) 2006-01-05
MXPA04006777A (es) 2004-11-10
US20050113435A1 (en) 2005-05-26
CA2473232A1 (en) 2003-07-24
WO2003059342A1 (en) 2003-07-24
AU2003235687A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
TW202409017A (zh) 雜環類化合物、其製備方法及其在醫藥上的應用
JP5617919B2 (ja) テトラヒドロベンゾチオフェン化合物
CN111065390B (zh) Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
CA2473232C (en) Histamine-3 receptor ligands for diabetic conditions
US20040220170A1 (en) Pyrazole-amides and sulfonamides as sodium channel modulators
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
TW200403210A (en) Benzamide derivatives
AU2015336458B2 (en) KCNQ2-5 channel activator
CN108602821A (zh) 1h-咪唑并[4,5-b]吡啶基和2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶基杂环bet溴结构域抑制剂
US20040209928A1 (en) Glucagon receptor antagonists/inverse agonists
CN111655693A (zh) 抑制瞬时型感受器电位a1离子通道
CN1956962B (zh) 四氢异喹啉磺酰胺衍生物,其制备方法及其在治疗中的应用
US20030153548A1 (en) Histamine-3 receptor ligands for diabetic conditions
JP2002522423A (ja) α1A作動薬としてのイミダゾール及び関連化合物
WO2025067219A1 (zh) 杂环类化合物、其制备方法及其在医药上的应用
WO2020132636A1 (en) Analogues of pentamidine and uses therefor
CA3035205A1 (en) Substituted ureas and methods of making and using same
CN116438177A (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
CN120774886A (zh) 芳香环类化合物、其制备方法及其在医药上的应用
CN121627648A (zh) 芳香环类化合物、其制备方法及其在医药上的应用
US20050171195A1 (en) P2X7 antagonists for treating neuropathic pain
CN121226319A (zh) 烯基取代的哌啶类化合物及其药物组合物、制备方法和用途
EP4353712A1 (en) New n-heteroarylbenzamides derivatives as flt3 inhibitors
JPS59231057A (ja) カルボン酸アミド化合物およびその誘導体
IL319492A (en) A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150112